Recent actions by the Food and Drug Administration (FDA) to approve a new generic version of the abortion pill mifepristone under the Trump administration have drawn heavy criticism from some conservatives. The backlash stems from the view that the decision undermines the anti-abortion movement and increases access to abortion. Background on the generic drug approval On or around September 30, 2025, the FDA approved a generic version of mifepristone from the drugmaker Evita Solutions. Mifepristo

NEW: U.S. Food and Drug Administration full approval of Pfizer vaccine "opens the door for more universities, businesses, corporations, even local and state governments to mandate the vaccine," Dr. Alok Patel tells ABC News. "Hopefully what this means is that people out there who wanted to wait and see, or wanted to see more safety data, got exactly what they wanted this morning," Patel says. abcn.ws/3B9ClDn | ABC News